原发中枢神经系统淋巴瘤放疗价值  

The value of radiotherapy for primary central nervous system lymphoma

作　　者：袁媛[1] 朱苏雨[1] 周菊梅[1] Yuan Yuan;Zhu Suyu;Zhou Jumei(Department of Abdominal/Lymphoma Radiation Oncology,Hunan Cancer Hospital,Changsha 410000,China)

机构地区：[1]湖南省肿瘤医院腹部/淋巴瘤放疗科,长沙410000

出　　处：《中华放射肿瘤学杂志》2024年第6期572-577,共6页Chinese Journal of Radiation Oncology

基　　金：湖南省卫生健康委科研计划课题项目(C2019072)。

摘　　要：原发中枢神经系统淋巴瘤(PCNSL)是一类预后相对较差的疾病,放疗是其重要的治疗手段之一。但是,随着以大剂量甲氨蝶呤为基础的诱导化疗和自体造血干细胞移植巩固治疗的广泛应用,以及全脑放疗对认知功能的损伤,放疗的价值在近十年备受争议。本文基于文献从放疗在PCNSL各个治疗阶段的应用、放疗靶区及剂量选择两个方面展开综述,探讨放疗在PCNSL治疗中的价值。Primary central nervous system lymphoma(PCNSL)is a disease with relatively poor prognosis,and radiotherapy is one of the important treatment methods.However,with the widespread application of high-dose methotrexate-based induction chemotherapy regimen and autologous hematopoietic stem cell transplantation consolidation therapy,as well as the impairment of cognitive function after whole brain radiotherapy,the value of radiotherapy has been controversial in the past decade.This article reviews the application of radiotherapy in various treatment stages of PCNSL,the selection of radiotherapy target area and dose,and discusses the value of radiotherapy in the treatment of PCNSL.

关 键 词：淋巴瘤 中枢神经系统肿瘤 全脑放射疗法 自体造血干细胞移植 

分 类 号：R739.4[医药卫生—肿瘤]